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Pregnancy is associated with several physiological changes that can alter the 
pharmacokinetics (PK) and necessitate dosing regimen changes for certain drugs in order to 
achieve drug exposures that are comparable to non-pregnant population. However, limited data is 
available in pregnant women in order to make rational drug dosing recommendations. Therefore, 
dosing recommendations for drugs, including treatment for opioid addiction, are usually 
extrapolated from studies carried out in non-pregnant patients. Among the reasons for lack of 
data is the difficulty associated with collection of multiple blood samples in opioid addicted 
pregnant women. Permanent damage caused to veins due to chronic IV drug use in these patients 
makes it especially challenging to obtain venous blood samples. Application of micro blood 
sampling as a tool for remote blood sampling can offer a convenient way for performing studies 
in this population. A novel micro blood sampling device called Volumetric Absorptive micro 
sampling (VAMS) developed in 2014 has resolved sample inhomogeneity issues inherent with 
previous dried blood Spot (DBS) techniques. The VAMS technique has also demonstrated 
improved precision in the volume of sample collected. Proper experimental design and 
optimization of the extraction of drugs and metabolites of interest are the key parameters in the 
application of a VAMS approach. Our study objective is to evaluate the utility of a micro 
sampling approach for self-collection of blood samples in order to monitor buprenorphine 
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concentrations and to optimize the dosage of buprenorphine in pregnant and post-partum 
patients.  
In this study, we have developed and validated an LC-MS/MS assay to measure Buprenorphine 
and attempted to quantify metabolites of the parent drug in whole blood samples simultaneously 
from the VAMS device, that can be of help in future studies in pregnant and postpartum subjects.    
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1.0 Introduction 
1.1 Opioid Use Disorder 
Opioids are substances that interact with the opiate receptors in the body. The ability of opioids 
to cause addiction goes hand in hand with their analgesic benefit, leading to a conflict among 
clinicians whether to prescribe them to relieve pain and cause long term damage due to 
addiction. After binding to opioid receptors, these agents also induce release of dopamine and 
activate the “reward circuits” in the brain, leading to a euphoric effect. On repeated exposure to 
the drug, brain cells become less responsive and higher doses are required to produce the same 
level of dopamine, hence tolerance develops. Long term use of opiates can potentially result in 
damage to the brain and lead to drug seeking behavior, making them highly addictive[6].   
The chronic use of opioids leading to an overwhelming desire to obtain such drugs 
despite professional or social consequences, marked by increased tolerance and withdrawal upon 
discontinuation are hallmarks of opioid use disorder (OUD). It is an epidemic in the United 
States and costs the nation over $600 billion annually. Out of the 20 million Americans who 
abuse substances, two million individuals use prescription opioids including oxycodone, 
hydrocodone, and fentanyl and 500,000 use heroin[7]. The disorder prevalence varies by age and 
gender, however women who become pregnant are not spared in this healthcare crisis. According 
the Centers for Disease Control, prevalence of OUD during pregnancy has more than quadrupled 
from 1999 to 2014[8].  
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1.2 Current Treatments for opioid addiction 
Treatment of OUD requires long term management, which is carried out through use of 
medications as well as psychosocial and behavioral treatment. However, psychosocial 
interventions or behavioral interventions alone are associated with poor outcomes for patients[9]. 
Currently, the best opportunity for treatment from opiate addiction is through medication-
assisted treatment (MAT), in combination with counseling therapy. The Food and Drug 
Administration has approved three medications for long term treatment of addiction: methadone, 
buprenorphine, and naltrexone.  
1.2.1 Methadone 
In 1964, Vincent Dole pioneered the use of methadone to treat opioid addicts. [10] The 
drug was then approved for treatment under strict supervision of opioid treatment clinics under 
the Narcotic Addict Treatment Act of 1974[11]. Methadone is currently the gold standard of 
therapy for OUD.   
Many clinical studies have proven its effectiveness in maintenance therapy for reducing 
illicit opioid use, reducing cravings, and improving patient’s social productivity[12].  
Methadone has properties similar to morphine, and binds to mu-, delta-, and kappa- 
opioid receptors. The drug has very slow onset of action with a half-life ranging from 24 to 36 
hours and is administered as a racemic mixture of both (R) and (S)-methadone. Since it is a long-
acting opioid, it has a better safety profile with less severe withdrawal syndrome compared to 
short-acting opioids like heroin[11, 13, 14]. 
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Upon oral administration, the drug is well absorbed with a bioavailability of 
approximately 75%. As a basic drug, it is predominantly (88%) bound to alpha-1-acid 
glycoprotein[15]. Methadone undergoes N-demethylation to form inactive metabolites by 
CYP3A4, CYP2B6 and CYP2C19[16]. 
However, because it is a full agonist of the mu- opioid receptor, the risk of abuse is 
greater. There can also be significant interindividual variability in methadone exposure  at a 
given dose[17, 18].  
1.2.1.1 Methadone Use in Pregnancy 
Methadone is the standard of care for MAT in pregnancy. If a patient is already receiving 
care in a methadone clinic, pregnancy may not interrupt this regimen. There is strong evidence, 
however, that dose alterations have to be made during pregnancy for methadone. Only 8% of 
patients are on the same dose of the drug throughout pregnancy[19]. As gestation advances, the 
dose of the drug has to be increased. Since the drug is eliminated very slowly, it is advisable to 
increase the dose gradually[20]. 
Plasma levels of methadone decrease, and renal clearance increases as gestation 
advances[21]. Therefore, cravings may become apparent before each dose. Split dosing or twice 
daily dosing every 12 hours has also been suggested but is not possible for all the patients since it 
would require take-home doses. Methadone is import regulated by state law and requires long 
standing proof of compliance (up to 2 years-meeting specific criteria) , therefore take-home 
doses are not feasible for most patients[22]. There exists high interindividual variability during 
pregnancy in the metabolism of methadone, signs and symptoms of withdrawal and increased 





Figure 1: Structure of Buprenorphine 
 
Buprenorphine is a semi-synthetic derivative of the alkaloid thebaine. It was developed by 
Reckitt and Coleman since they were searching for a morphine-like compound which retained 
the analgesic property of morphine while demonstrating less potential for addiction and 
withdrawal. The FDA approved buprenorphine for treatment of opioid addiction in 2002.  
Being a partial agonist, it has a very unique pharmacological profile compared to that of 
methadone and morphine. Buprenorphine has high binding affinity for the mu-opioid receptor 
but low intrinsic activity. Therefore, even at high doses of the drug, when it binds all the mu 
receptors, it does not show maximum opioid agonist effect. 
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Figure 2: Partial Agonist activity 
 
This has been supported by the bell-shaped dose response curve of anti-nociception effect in 
animal studies, where the agonist activity shows a ceiling effect at high doses of the drug[24]. 
Apart from binding to the mu-receptor, buprenorphine also binds to other opioid 
receptors. It has no intrinsic activity on the delta-opioid receptor and low activity on the kappa 
opioid receptor[25, 26]. 
Buprenorphine undergoes extensive first-pass metabolism, therefore has very low oral 
bioavailability. It is administered through parenteral, sublingual, transmucosal, subcutaneous or 
transdermal routes and not orally for this reason[27]. Buprenorphine is commonly formulated in 
combination with Naloxone. Since naloxone acts as a full opioid antagonist, it reduces risk of 
abuse and decreases the attractiveness to inject the drug in addicted patients.  
Many studies have reported high interindividual variability in buprenorphine 
pharmacokinetics following sublingual administration. Ciraulo et al. found that the coefficients 
of variation in maximum plasma concentration (Cmax) and the area under the curve (AUC) 
ranged from 40-64%[28]. Absorption after sublingual dose is rapid, however the time to reach 
plasma peak concentration (Tmax) ranges from 1 to 6 hours.  The longer time to reach plasma 
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peak concentration might be due to the slow release because of depot effect by sequestration of 
the drug in the oral mucosa[29]. 
Buprenorphine is lipophilic drug with a logarithm of the octanol to water partition 
coefficient (LogP) of 4.98[30]. Because of this, it readily penetrates tissues and crosses the blood 
brain barrier. It is a basic drug (pKa1=9.62, pKa2=8.31), which is highly bound to alpha and beta 
globulin(96%)[30] The apparent volume of distribution at steady state following intravenous 
administration is 335 L. Buprenorphine has a long plasma half-life ranging from 24-42 hours, 
following sublingual or transmucosal administration[31].   
Table 1: Advantages and Disadvantages of Buprenorphine 
Advantages Disadvantages 
1. Sublingual formulation 
2. Allows for once daily or three times weekly 
dosing 
3. Potent as an analgesic 
4. Does not affect immune/endocrine system 
5. Ceiling effect for respiratory depression 
6. Wide safety margin regarding dose 
7. Slow dissociation leads to reduced 
withdrawal symptoms 
1. Expensive 
2. Slow onset 
3. Drug-drug interactions with CYP3A4 
substrates 
4. Need high doses of naloxone for reversal 
5. Can cause QTc prolongation at high doses 
 
After intravenous administration, plasma clearance of BUP is around 50L/hr in healthy 
volunteers[32]. When we compare BUP blood clearance with hepatic blood flow in healthy 
subjects, the estimated extraction ratio of the drug is 0.9 which indicates it to be a high hepatic 
clearance drug.  
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The primary metabolic pathway of the drug is via CYP3A4 mediated N-dealkylation to 
form norbuprenorphine. Norbuprenorphine undergoes further conjugation to form 
norbuprenorphine glucuronide through UGT1A1 and UGT1A3[33]. A part of buprenorphine is 
also directly conjugated to buprenorphine glucuronide. Therefore, overall CYP3A4, CYP2C8, 
UGT1A1, UGT1A3 and UG2B7 are involved in metabolism of the parent drug buprenorphine.  
Of the known metabolites, norbuprenorphine is the major metabolite which also exhibits 
agonist activity. In vitro studies have found that norbuprenorphine has high affinity to the mu-
receptor, comparable to that of buprenorphine[34]. In rat studies, norbuprenorphine led to 
respiratory depression and showed up to 10 times more potency than buprenorphine[35].  
While norbuprenorphine is a potent mu-receptor agonist, brain concentrations of the 
compound are very low. Norbuprenorphine is more hydrophilic than the parent drug, so it cannot 
pass through to the brain easily. This indicates that the metabolite may not contribute to the 
clinical effects of the parent drug.[36] It has been generally accepted that the glucuronide 
metabolites are inactive, however Brown et al. conducted a study which showed that 
buprenorphine-3-glucouronide had mild antinociceptive activity in a mouse model, and 
norbuprenorphine-3-gluconide had sedative effect and decreased respiratory tidal volume[37]. 
These findings add to the complexity of buprenorphine pharmacology and make it difficult to 




Figure 3: Buprenorphine Metabolic Pathway 
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1.3 Medication Assisted Treatment during Pregnancy 
The 2010 National Survey on Drug Use and Health by the National Institutes of Health 
(NIH) reported a 47% increase in illicit drug use during pregnancy since 2002 (4.4% in 2010 
versus 3% in 2002 for the age group of 15 to 44 among pregnant women)[38]  
Use of opioids during pregnancy can lead to a drug withdrawal syndrome in newborn 
babies known as neonatal abstinence syndrome (NAS). Apart from the development of NAS, 
maternal opioid use is associated with many complications such as maternal death, cardiac arrest, 
intrauterine growth restriction and placental abruption, birth defects, still birth and preterm 
labor.[39, 40] 
Ideally, the woman should abstain from opioids completely during pregnancy and many 
women are motivated to reduce illicit opioid use to provide the best outcome for their children. 
However, there are significant risks associated with abrupt stopping of opioids since the pregnant 
women would undergo intense withdrawal symptoms during detoxification which would lead to 
intrauterine stress and preterm labor, directly impacting fetal development[41].  
Currently, the treatments for OUD in pregnant women are medication assisted 
maintenance therapy using long-acting mu-opioid receptor agonists such as methadone or 
buprenorphine[42]. Although methadone has been used for many decades and many studies have 
shown its effectiveness in pregnancy, there are several issues with this drug. Women prescribed 
methadone need to be under strict monitoring and attend a clinic daily to obtain the medication. 
In the US, women who suffer from severe opioid addiction tend to be prescribed methadone 
while women who have lower risk of relapse are prescribed buprenorphine[43].  
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Altered metabolism of methadone has been reported in several studies in pregnant 
women[44, 45]. Patients taking higher doses of methadone still show low trough plasma 
concentrations of the drug during pregnancy[45]. Moreover, the higher maternal methadone dose 
is associated with increased incidence of NAS[46].  
Buprenorphine has comparable efficacy to methadone and shows significantly lower 
severity and incidence of NAS[43] Neonates exposed to BUP require up to 89% less morphine to 
treat NAS, a 43% shorter hospital stay, and a 58% shorter duration for treatment compared to 
methadone[47]. Moreover, buprenorphine is theorized to be a safer alternative to methadone due 
to its partial agonist property itself. As mentioned previously, the long half-life of buprenorphine 
is convenient, and it may be dosed 3 times/week compared to the daily dosing of methadone.  
There is limited data on the alteration of BUP pharmacokinetics and pharmacodynamics 
during pregnancy, and therefore the dosing regimen for pregnant women is based on the 
recommendations derived for non-pregnant women and men. In order to understand the efficacy 
of BUP and methadone in pregnant populations, Jones et al. conducted a study and found that 
33% of patients in the buprenorphine group terminated treatment early compared to 18% in the 
methadone group. More than 71% of the dropout was because of patient dissatisfaction with 
BUP. There was no such difference in retaining patients for the non-pregnant population, 
however[48].  
Studies conducted at Magee Women’s Hospital Pittsburgh also indicate an increase in 
BUP dose requirement during pregnancy[49].  Therefore, the lack of clear data and broad dosing 
range may be causing a dosing bias among individual physicians and might be affecting the 
patient satisfaction on BUP therapy. Since both intrinsic clearance and hepatic blood flow can 
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impact BUP clearance, it is clear that pregnancy is associated with increased clearance and 
decreased exposure of the drug.  
Women with addiction also need to continue their opioid agonist therapy postpartum. The 
postpartum period is a time of heightened vulnerabilities, and the risk of relapse for women with 
opioid use disorder is much higher in the postpartum period than during pregnancy[50]. There 
tends to be limited access to adequate postpartum psychosocial support including relapse 
prevention programs or overdose training.  Therefore, there is a need to gain better understanding 
of pregnancy and postpartum changes in the elimination of BUP. The main challenge in dosing 
the drug in pregnancy is to maintain drug levels at an optimum range, keeping the patients 
satisfied, while minimizing drug exposure to the fetus. Currently there are several studies on 












1.4 Pregnancy induced physiological changes and impact on pharmacokinetics 
Pregnancy brings about many physiological changes and adaptation of organ systems in 
order to accommodate for the development of the fetus. Such pregnancy-induced physiological 
changes can significantly impact drug absorption, distribution, metabolism, and elimination[51].  
 
 







The movement of drug from the site of administration into the bloodstream is the process 
of absorption. During pregnancy, there is an increase in gastric pH which can lead to ionization 
of acidic drugs and affect their absorption into the gut wall. Similarly, as a result of decreased 
gastric emptying and intestinal motility during pregnancy, there may be a decrease in drug 
absorption rate[52, 53].  
1.4.2 Distribution 
The process of drug movement into various tissues once it has entered the body, is 
referred to as distribution. Physicochemical properties of the drug can affect the extent to which 
drug distributes within the body. For instance, the drug’s lipid solubility (LogP), pKa and 
partition coefficient can significantly impact its passage through biological membranes. Since 
only the unbound fraction of the drug can cross cell membranes, the fraction of drug bound to 
plasma is an important factor that affects its distribution. Volume of distribution (Vd) is a 
parameter to determine the extent of drug distribution within the body. During pregnancy, 
increases in total body water, body fat, plasma volume and blood volume impact the drug Vd. 
Therefore, increase in body fat would impact the Vd for lipophilic drugs and cause it to increase. 
Whereas, increase in plasma volume and total body water cause increase in Vd for hydrophilic 
drugs as well[5, 54].  
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1.4.3 Metabolism 
Conversion of drugs via enzymes to form more polar, hydrophilic compounds that can be 
easily eliminated is the process of metabolism. Factors that affect the hepatic clearance of the 
drug include intrinsic clearance, blood flow and unbound fraction of drug in blood.  
In terms of pregnancy, the effect on metabolism is drug specific. Metabolism of drugs 
mediated by CYP3A4, CYP2C9, CYP2D6, UGT1A4 and UGT2B7 is increased whereas 
metabolism of drugs mediated by CYP1A2 and CYP2C19 is decreased[5, 51, 55].  
1.4.4 Excretion 
The process of drug removal from the body is excretion. One of the primary organs 
involved in elimination is the kidney. Mechanisms of renal excretion are glomerular filtration, 
tubular secretion, and reabsorption. Since only unbound fraction of drugs is filtered by nephrons, 
it is one of the factors that affects renal clearance. Therefore, for a drug that only undergoes 
filtration as mechanism for renal clearance, the renal clearance is defined as product of 
glomerular filtration rate (GFR) and unbound drug fraction (fu). Since pregnancy causes increase 
in fu and GFR is also increased from 97 ml/min in non-pregnant women to 180 ml/min in 
pregnancy, renal clearance of drugs such as lithium is increased in pregnancy[56].  
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1.5 Difficulty in performing pharmacokinetic studies in pregnant women and alternative 
approaches to evaluate pharmacokinetics in pregnancy 
Since there are significant anatomical and physiological changes throughout the course of 
pregnancy, pharmacokinetics of several drugs is expected to be impacted in pregnancy. In order 
to properly characterize the pharmacokinetics of a drug, sufficient number of samples need to be 
collected to determine the time course of absorption, distribution, metabolism, and excretion 
from each subject.  
A typical PK study involves taking 9-12 blood samples over 3-5 half lives of the drug 
from each patient and requires them to be hospitalized or use Clinical Research Centers. The 
subjects have to agree to repeated invasive blood sampling approaches or insertion of a blood 
sampling catheter (heparin lock) over an 8–12-hour time period. Any study visits in the months 
following birth are challenging to the mother and this reality is a disincentive for participation in 
any research study. Such intensive blood sampling and the long duration of the study adds to the 
practical issue in studying pharmacokinetics of drugs in pregnant women.  
Moreover, pregnant women with opioid addiction are likely to suffer from coexisting 
mental health problems including depression, mood disorders, trauma, posttraumatic stress 
disorder and anxiety. They are at risk of abuse of other substances such as alcohol, tobacco, 
cocaine, and cannabis. Prolonged use of intravenous drug use also leads to permanent damage to 
the veins for these patients. This makes repeated venous blood sampling extremely difficult since 
there are not any perceptible veins to draw blood from. Most of these women suffer from 
inadequate nutrition and have disturbed support systems leading to social service needs. Frequent 
trips to the clinic can be a significant barrier for women without transportation or those from 
rural areas[20]. The ability for women to participate in research studies is limited with such 
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socio-economic disadvantages. In order to combat these barriers, several approaches may be 
considered as alternatives to a full PK study.   
Table 2: Overview of Strategies to Optimize Clinical studies(Adapted from Balevic et.al[57]) 
Outcome Innovative Approach 
Clinical Trial Optimization 
Optimizing Data collection and 
implementation 
Bioanalytical Optimization: micro 
sampling  
Reducing risk for participants Sparse Sampling 
Microdosing 
Opportunistic Study Design 
Simulation and Modeling 
Optimizing Study Design Simulations of Clinical Trials 
Predicting Effects of Organ 
Dysfunction 
PBPK 
Individualizing dose Population PK 
Bayesian Analysis 
 
There have been significant advances in analytical chemistry that have allowed the use of 
miniscule volumes of blood to be utilized for bioanalysis. As of yet, these sampling methods are 
underutilized due to lack of suitable assays developed for the same.  
Obtaining the same PK/PD information from minimally invasive approaches such as 
micro sampling can significantly reduce the burden on pregnant women to participate in research 
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studies. Such microliterµ blood samples can be taken by the patients themselves, dried under 
ambient conditions and sent to the lab for analysis. 
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2.0 The Micro sampling Approach 
There has been a trend towards precision medicine with an emphasis on personalized approach. 
In order to support this method, it is necessary to develop tools that improve sample collection 
and enable patients to actively participate in monitoring their own therapy. Micro sampling is a 
technique that utilizes very small amounts of biological matrix, typically less than 50 µL, for 
quantitative analysis. 
The origins of micro sampling can be traced back to 1913, where filter papers were used 
for the analysis of glucose. Micro sampling was first demonstrated by Ivar Bang[58] and further 
developed by Dr. Robert Guthrie. He presented the method of Dried Blood Spot(DBS) sampling 
for newborn screening of phenylketonuria[59], using filter papers for detection of the enzyme 
phenylalanine hydroxylase, which is a marker for phenylketonuria[60]. Since then, the use of 
DBS has become common for detecting sickle cell disease and human immunodeficiency virus, 
especially for mass studies in developing countries[61]. 
2.1 Traditional Method of Sampling and its Limitations  
The traditional venous blood sampling methodology requires patients to be in a health 
care facility or a clinical laboratory. This can be problematic when samples are to be taken from 
populations such as children and geriatric patients[62].Collection of samples in patients living in  
remote areas also becomes a challenge. A special application of micro sampling to opioid 
addicted pregnant populations is what we propose here.  
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The procedure for blood testing normally requires a phlebotomist to collect a substantial 
blood volume (typically 3 to 5 mL) intravenously using a needle attached to an evacuated blood 
collection tube[62].Vein puncture is carried out on the forearm of the patient while using a 
tourniquet to constrain the flow of blood. After collection, the samples will be sent to the central 
laboratory for analysis[63].   
The venipuncture method provides accurate diagnosis; however, it is costly and time-
consuming due to numerous logistical requirements. For instance, in a laboratory setting, the 
time needed for blood testing for a pharmacokinetic study ranges from hours to days depending 
on the drug and the study procedures[63]. 
The major potential sources of variation in plasma or serum include specimen collection 
method, transport, processing, and storage. There is evidence that the reliability of an analytical 
method is conditional on rapid separation of plasma and serum from blood. The need to have a 
centrifuge at the point of sample collection or soon after sample collection in a lab to separate the 
plasma and serum is may also present an issue in some cases.   
Blood as a matrix avoids several of the above concerns. With improvements in sensitivity 
of analysis, there has been a significant reduction in the sample size that is necessary for disease 
diagnosis. A smaller sample size overcomes the issues in conventional techniques thereby 
leading to potential for a minimally invasive diagnostic technique[64]. Repeated, large-volume 
sampling is uncomfortable for patients, especially for those with chronic conditions who require 
regular blood testing. The micro sampling approach is relatively less painful, with fewer 
requirements on handling and storage. Therefore, the use of micro sampling can cause a 




Table 3: Overview of Micro sampling Challenges (Adapted from Parker et al. [65]) 
Collection and sample parameters Blood DBS VAMS 
Routinely used for bio-analysis ✓   
Measure total drug concentrations ✓ ✓ ✓ 
Measure unbound drug concentrations ✓   
Minimally invasive sampling  ✓ ✓ 
Low Sampling volume (<100 µL)  ✓ ✓ 
Ease of sample handling  ✓ ✓ 
Cost saving on transport and storage  ✓ ✓ 









3.0 Dried Blood Spots 
 
Figure 5: Dried Blood Spotting Card 
The DBS technique involves the use of a blood lancet and a sample collection card or 
filter paper. After performing a finger prick, a few drops of the blood are adsorbed onto the filter 
paper. The sample is then dried for a period of 2-3 hours over an open non-adsorbent surface. 
These conditions can differ depending on the filter paper used, temperature and humidity of the 
surroundings[66] The DBS samples are then placed in plastic sealable bags containing desiccant 
and humidity card markers. The impact of sunlight, heat and moisture can thereby be minimized 
and avoid potential degradation of the analyte. Thereafter, a fixed diameter disc is punched from 
the sample. The punch size may vary from 3-6 mm to the whole spot, depending on the method 
used. The disc can be considered to provide a volumetric measurement, comparable to the usage 
of a pipette for liquids. After extraction, the analyte is measured using a suitable analytical 
method. 
The demand for sampling for DBS is a lot less than for phlebotomy, and the experimental 
set up does not require any centrifugation or sub-aliquoting of plasma[67]. Moreover, shipment 
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and storage requirements are simple and can be carried out at room-temperature for most tests. 
The DBS samples can be transported with no reasonable expectation of exposure to blood or 
other possibly infectious materials by the handlers unlike the shipment of liquid samples. It can 
be sent via normal post without specialized mailing cartons or packaging. Most analytes are 
more stable in DBS than even in frozen samples[68].  
3.1  Applications and Drawbacks of Dried Blood Spots 
The application of this technique is widespread in toxicology, including epidemiology, 
environmental and forensic toxicology[69]. The stabilizing effect of a dried sample in slowing 
down degradation has proven to be beneficial. It also offers the potential to analyze biomarkers 
of exposure, including DNA adducts and protein adducts.  
Therapeutic Drug Monitoring is a field gathering increasing attention in the application of 
minimally invasive blood sampling strategies. The possibility for at home-sampling, along with 
the noncontagious nature of DBS, makes it appropriate for TDM. There have been publications 
of DBS-based TDM for multiple drug classes-including antiepileptics, antiretrovirals, 
immunosuppressants, antimalarials, antibiotics and others. 
However, the DBS technique has major drawbacks in drug quantification and analysis. 
Extensive validation of the assay protocol is required. 
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Figure 6: Composition of Blood 
 
Hematocrit (HCT) has been currently identified to be the single most important parameter 
affecting the spread of blood on DBS cards. This can have an effect on the spot size, drying time 
and eventually the robustness and reproducibility of the assays. Since HCT levels are correlated 
with blood viscosity, a higher HCT value would lead to the blood spot spreading to a lesser 
extent, with a smaller diameter on the paper. The influence of differences in hematocrit values on 
the spot size and homogeneity has to be accounted for in the assay performance.  For instance, 
there is an increased risk of negative bias in the result when the blood spots are smaller in 
size[70] 
 
Other factors that affect the DBS assays include the environmental conditions and storage 
temperature at the time of collection. For example, when samples were stored over a year at 
20⁰C, they showed greater deterioration compared to samples stored at a lower temperature of 
4⁰C for the same time period[71]   
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3.2 Volumetric Absorptive Micro Sampling 
Another approach is to make use of devices, which help with collection of a fixed volume of 
blood avoiding any impact of HCT. In 2014, the company Neoteryx came up with a proprietary 
micro sampling device called Mitra® based on the principle of Volumetric Absorptive micro 
sampling (VAMS). It allows for collection of an accurate volume of blood each time it is dipped 
into a drop of blood after finger pricking with a lancet. Many studies have been carried out using 
this device, documenting lack of any hematocrit bias with samples having hematocrit values  
ranging from between 20 to 70% with a 10 µL blood volume capture[72]. The Mitra 
device has been designed to provide all the benefits of the DBS technique, while overcoming the 
hematocrit bias as well as providing simpler workflow for analysis of blood samples. It has also 
been shown that the VAMS method is accurate and reproducible when sampling is carried out at-
home[73]. Practically, the use of VAMS also facilitates sample identification during analysis, 
which is not the case with DBS, since it cannot be identified once it has been punched[65].  
The distinct advantage of using VAMS is that it complies with the 3Rs principle which 
helps reduce the number of animals tested as well as help curb the pain that animals face during 
sampling. Collection of smaller blood sample volumes from rodents in PK studies permits a 
larger number of samples to be collected from a single animal.  
For VAMS, we would only need to take 10 µL sample at a single time point compared to 
approximately 200-500 µLs in using other approaches for PK studies. Considering the blood 
volume of rodents (55-70 mL/kg body weight), a cumulative amount of 0.3 mL blood can be 
withdrawn each day for a rat weighing 350-500 g. Therefore, multiple blood samples can be 
obtained in a single day from a rodent without sacrificing the animal, leading to improved 
pharmacokinetic profiles from one animal [74].   
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3.2.1 Sampling Process 
The device is available in configurations that allow for accurate sampling of 10, 20 and 
30 µL. The device consists of a proprietary adsorbent tip attached to a plastic handle with 
grooves for ease in gripping. A finger or heel prick has to be carried out, following which, the 
adsorbent sampling tip is held and dipped at an angle of 45⁰, allowing only the leading surface of 
the tip into the drop of blood which enables the uptake due to capillary action. The tip may be 
held in contact with blood pool for an additional 2-3 seconds to ensure complete filling. 
However, issues with overfilling of the tip have been reported. Double-dipping or keeping the 
tips in contact with blood longer than 6 seconds are likely to cause variations in volume.[75]  
Re dipping the tip while they are still wet does not cause any major impact on the volume 
sampled. As time between the first and second dip increases, there is an impact on the result. 
This situation however should not occur since the practical application of VAMS is related to 
finger/heal prick and re dipping would be occurring within seconds of sampling. Utmost care 
needs to be taken that the tips do not touch surrounding surfaces. Once the tips have been 
suitably loaded with blood, they need to air dried prior to further processing. The dried tips can 
also be placed at RT in plastic pouches with desiccant[72].The device is self-indicating, since the 
tip turns completely red which signals it is filled to its capacity. Since the tip wicks the blood, it 
acts like a pipette absorbing the accurate blood volume which eliminates volume related 
variations to a major extent. Moreover, the tip is attached to a plastic handler, so it does not come 
in contact with any surface.  
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3.3 Objective of the Present Study 
Between 2000 and 2009, the rate of opioid use among pregnant women increased 5-fold. 
The efficacy of buprenorphine to suppress withdrawal symptoms in these women is comparable 
to that of methadone. However, a large cohort of clinical trials that compared the efficacy of 
buprenorphine and methadone in pregnant patients reported that 30% of patients converted to 
buprenorphine stopped initially, and 71% of them dropped out due to dissatisfaction with the 
drug. This is likely due to the various physiological changes during pregnancy that potentially 
affect buprenorphine disposition and impact its efficacy.  
Use of medications during pregnancy based on dosing recommendations for non-
pregnant populations, without titration of its dose to account for the altered PK changes may lead 
to therapeutic failure or toxicity for the patient as well as the fetus. We predict that 
buprenorphine exposure will decrease due to an increase in the total body clearance of the drug 
during pregnancy. Previous studies carried out in our lab have documented lower exposure of 
BUP during pregnancy[49]. However, further data is needed to characterize the pharmacokinetic 
profile of buprenorphine in a larger patient population. The use of a micro sampling method to 
collect blood samples from these pregnant patients will eliminate the inconvenience encountered 
due to long hours spent in the clinic for multiple sample time points.  
 
We hypothesize that a micro sampling tool such as the VAMS device will help facilitate 
conduct of pharmacokinetic studies in pregnant women and can provide substantial data to 
predict alterations in the clearance and exposure of buprenorphine during and after pregnancy.  
It is necessary to first develop a sensitive and specific assay for determining 
buprenorphine and its metabolites in the 20 µL VAMS blood sample. To date, no method has 
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been developed to simultaneously quantify buprenorphine and its metabolites using 20 µL 
VAMS samples.  
The goal of this study is to develop and validate a highly sensitive and reproducible LC-
MS/MS micro sampling assay for buprenorphine and its metabolites and apply this method to 
process VAMS samples from clinical pharmacokinetic studies in pregnant women. The ultimate 
application is to optimize buprenorphine dosing in treating opioid addiction in pregnancy and 
post-delivery through a better understanding of the effect of pregnancy on BUP exposure.  
Through the proposed experiment, we have attempted to develop and validate a simple 
and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay to quantify 
buprenorphine and three primary metabolites (norbuprenorphine, buprenorphine glucuronide, 
norbuprenorphine glucuronide) in 20 µL VAMS blood samples.  
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4.0 Materials and Methods 
4.1 Chemicals and Reagents 
Chemical structures of buprenorphine, norbuprenorphine, buprenorphine glucuronide, 
norbuprenorphine glucuronide and respective deuterated internal standards, buprenorphine-D4, 
norbuprenorphine-D3, buprenorphine-D4-3-β-D-glucuronide, norbuprenorphine glucuronide-D3 
are shown in Figure 7. They were purchased from Sigma-Aldrich (St. Louis, MO). Ammonium 
acetate (99.9999 trace metals basis) and OptimaTM LC/MS grade acetonitrile, formic acid, 
methanol, and water were obtained from Fisher Scientific (Fair Lawn, NJ, USA). Human blood 
samples were procured from central blood bank of Pittsburgh (Pittsburgh, PA, USA). 20 µL 
VAMS devices were obtained from Neoteryx, Torrance CA, USA.  
4.2 Chromatographic Conditions 
The LC system used for the analysis of buprenorphine and three of its metabolites was a 
Waters Acquity H class model (Waters Corporation, MA, USA). Separation of all components of 
interest was achieved on Acquity LC BEH C18 1.7 μm, 2.1 x 100 mm column. The mobile phase 
A was 5% acetonitrile in water containing ammonium acetate (2 mM) and formic acid (0.1%) 
and mobile phase B was 95% acetonitrile in water containing ammonium acetate (2 mM) and 
formic acid (0.1%) at a flow rate of 0.3 mL/min. A sample volume of 5 μL was injected on 
column. A gradient method for the mobile phase was used to separate buprenorphine and its 
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three metabolites. The gradient started at 25% of B, maintained for 1.0 min, then increasing to 
35% of B from 1.0 min to 1.1 min, maintaining for 2 min, then increased to 100% of B from 3.1 
to 4.1 min, maintaining for 2 min, and decreased to 25% of B from 5.1 to 5.2 min, then 
maintained at 25% of B until 7 min. The gradient method is summarized in Table 4. The total run 
time for each injection was 7 mins. 
Table 4: Gradient Method used to separate BUP and its metabolites 
Run Time (min) Mobile Phase A % Mobile Phase B % 
Up to 1.0  75 25 
1.1 65 35 
3.1 65 35 
4.1 0 100 
5.1 0 100 
5.2 75 25 







Figure 7: Chemical structure of buprenorphine (A), buprenorphine-D4 (B), norbuprenorphine (C), norbuprenorphine-D3 (D), buprenorphine-3-β-D-
glucuronide (E), buprenorphine-D4-3-β-D-glucuronide (F), norbuprenorphine glucuronide (G), norbuprenorphine glucuronide-
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4.3 Mass spectrometric conditions 
Mass spectrometric analysis was carried out using a XEVO TQS triple quadrupole mass 
spectrometer (Waters, Milford, MA, USA) with positive electric spray ionization mode using 
multiple reaction monitoring (MRM). Multiple reaction monitoring used the precursor to product 
ion pairs for quantification of compounds used by MRM are summarized in Table 5 below.  
Table 5: Product ion pairs-MRM Method 
Compound Parent (m/z) Daughter (m/z) 
Buprenorphine 468.5 396.3 
Buprenorphine-D4 472.2 400.2 
Norbuprenorphine 414 101 
Norbuprenorphine-D3 417.3 101.1 
Buprenorphine-3-β-D-glucuronide 644.1 468.2 
Buprenorphine-D4-3-β-D-glucuronide 648.6 472.5 
Norbuprenorphine glucuronide 590.1 414.2 
Norbuprenorphine glucuronide-D3 593.5 417.4 
 
The settings of MRM were as follows: capillary voltage, 2.8 kV; source temperature, 
150°C; desolvation temperature, 500 °C; cone gas flow, 150 L/h; desolvation gas flow, 800 L/h. 
The LC–MS system was controlled by Masslynx® software version 4.2, and data were collected 
with the same software 
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5.0 Studies Conducted 
 
 
Figure 8: Preanalytical Considerations 
 
The ideal solvent for extraction provides maximum analyte recovery, with high 
reproducibility and minimal interference from other compounds. Assay performance is impacted 
by the blood absorption onto tips, analyte recovery as well as the matrix effect.  
Optimization of the extraction recovery is critical to eliminate the extractability-mediated 
stability bias as well as the hematocrit effect[76].  
While developing an assay method for VAMS, two stages of sample extraction need to be 
considered. The first stage is desorption where the dried blood needs to be desorbed from the 
polymeric tip by use of an aqueous solution along with high energy sonication and vortexing in 
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order to ensure all of the blood has been displaced from the dried matrix. The composition of 
liquid blood that has been desorbed from VAMS tips is different from original liquid blood[77]. 
The second stage is the analyte extraction stage, wherein protein precipitation or liquid-liquid 
extraction are utilized.   
There are differences in opinion about whether the IS should be added to fluid matrix 
before VAMS sampling or if the IS should be soaked into the tips after test tube sampling. 
According to Marasca et al, the results are overlapping either way. However, the extraction 
process described by Mohamed et al. emphasizes on addition of IS during the VAMS treatment 
step, rather than to the blood before the tips are sampled. This also reflects the real-life scenario 
where the blood is sampled by finger prick and then processed in IS solution later.[78-80] 
5.1 Gravimetric Volume estimation 
Typically, the devices are weighed before and after blood absorption in order to 
determine the volume of blood collected within the VAMS tip by considering the density of the 
blood matrix. This volume sampling test was carried out in the determination of Acetylsalicylic 
acid by Kim et al. using the given formulae[81]:  
Average density of matrix-  
Matrix density (mg/μL) = Mean blood weight in 20 μL aliquot (mg)/20 
Volume of blood absorbed onto the VAMS tip-  
Mean matrix volume in VAMS tip (μL) = [Mean blood weight in VAMS tip (mg)/ mean 




Assuming density of blood: 1060 kg/m3 or 1.06 g/ml 
Table 6: Gravimetric Volume Estimation of VAMS device  
Dry weight Wet Weight Difference Volume 
Bias (%) 
g g g Mean (µLs)  
1.19 1.21 0.03 24.8 24.2 
1.19 1.21 0.02 20.3 1.5 
1.20 1.23 0.02 22.8 13.9 
1.13 1.16 0.02 23.2 16.0 
1.16 1.18 0.02 22.4 11.8 
1.19 1.21 0.02 21.3 6.5 
 
We can conclude that majority of samples (83%) have a bias within 16% of the 
theoretical volume, which is acceptable for our studies. 
5.2 VAMS-Internal Standard Interaction  
The next step that we had to verify was whether presence of VAMS led to adsorption of IS. In 
order to understand this, we tested the internal standard response in the presence of three solvents 
along with the VAMS device tip.  
1. 5% Methanol 
2. 100% Acetonitrile 




Figure 9: Internal Standard Response 
In Figure 9, the control sample is denoted in grey which refers to the blood standard extracted 
using each of the solvents mentioned, without the presence of VAMS tip. The test sample is 
denoted in blue wherein the blood standards were absorbed by VAMS tip and subjected to the 
same extraction process. As we can conclude from the figure, extraction of VAMS with 
commonly used solvents such as 5% Methanol as well as 100% aqueous solution did not 
significantly affect the IS response. 100% Acetonitrile was ruled out as an extraction solvent due 
to poor response compared to that of the control. Moreover, since the Internal Standard Solution 
itself contains Acetonitrile, it would not be suitable as an extraction solvent regardless. Very high 
proportion of acetonitrile would lead to protein precipitation within the tip, entrapping the 







5.3 Aqueous vs Organic Solvent for Extraction 
Table 7: Results for VAMS-BUP Standard conc 100 ng/mL 
Name Retention Time Area           IS Area 
Response= 
Area/IS Area 
BUP 10% Methanol  3.14 96433 28284 3.5 
BUP 25% Methanol  3.1 60813 16293. 3.7 
BUP 50% Methanol  3.1 60789 16806 3.6 
BUP 100% Methanol  3.11 58903 31891 1.8 
BUP 100% Methanol  3.1 55493 29038 1.9 
 
 










As shown in Table 7, we tested 10%, 25%, 50% and 100% Methanol solutions for extraction of 
BUP and its metabolites from the VAMS device.  
After testing pure organic solvents such as 100% Methanol and 100% Acetonitrile, it was clear 
that an aqueous medium would be necessary in order to desorb blood from the VAMS device 
and diffuse into solution, since blood is mainly composed of aqueous media along with proteins 
and lipids.  
 
Figure 10: Aqueous Solvent to desorb blood 
 
Since increasing the proportion of methanol in the solution did not show significant 
improvement in response, 5% Methanol was selected as optimum extraction solvent. 
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Figure 11: Standard Curves for (A) Buprenorphine (B) Norbuprenorphine (C) Buprenorphine-3-glucouronide (D) Norbuprenorphine-3-glucouronide 
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Table 9: Standard Curve Data for Buprenorphine, Buprenorphine G, Norbuprenorphine, Norbuprenorphine G 
Name RT Area IS Area Response 
BUP-100 pg mL 3.16 24.5 5615.8 0.004 
BUP-500 pg mL 3.17 74.6 4891.3 0.015 
BUP- 2 ng mL 3.17 575.9 4607.1 0.125 
BUP-5 ng mL 3.16 1324.5 4380.2 0.302 
BUP-20 ng mL 3.16 4808.6 5028.5 0.956 




























Name RT Area IS Area Response 
BUPG-200 pg mL 1.36 192.8 43323.2 0.004 
BUPG-1 ng ml 1.35 1050.9 49799.7 0.021 
BUPG- 4 ng mL 1.35 4303.7 52055.1 0.083 
BUPG-10 ng mL 1.35 9354.3 49499.5 0.189 
BUPG-40 ng mL 1.35 41238.8 50994.1 0.809 
BUPG-200 ng mL 1.35 206376.9 48665.7 4.241 
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Table 9: (Continued) 
Name RT Area IS Area Response 
NBUP- 100 pg mL 1.65 5.1 3994.3 0.001 
NBUP- 500 pg mL 1.65 56.8 3198.5 0.018 
NBUP- 2 ng mL 1.64 276.9 3528.2 0.078 
NBUP-5 ng mL 1.64 527.3 3318.9 0.159 
NBUP-20 ng mL 1.64 2614.3 3548.4 0.737 











Table 9: (Continued) 
 
`Name RT Area IS Area Response 
NBUPG-200 pg mL 0.85 44.1 6092.8 0.007 
NBUPG-1 ng mL 0.86 196.9 6646.1 0.03 
NBUPG- 4 ng mL 0.86 833.4 6369.6 0.131 
NBUPG-10 ng mL 0.87 1759.1 6457.3 0.272 
NBUPG-40 ng mL 0.86 6590.1 6140.9 1.073 
NBUPG-200 ng mL 0.86 33963.4 6282.1 5.406 
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While testing for standard curve concentrations of 0.1, 0.5, 2, 5, 20, 100 ng/ml of Buprenorphine, 
response for BUP as well its metabolites were consistently suitable using 5% Methanol as 
extraction solvent.  
However, while checking response for low standard concentrations of 0.1-10 ng/ml of the drug 
which reflects clinical concentration levels, the BUP samples showed unacceptable recovery, as 
pictured in Figure 12.  
 
Figure 12: Unacceptable BUP Response 
 
The issue of poor recovery of BUP has been consistent throughout assay development by use of 
5% Methanol as extraction solvent, with NBUP, NBUP-G and BUP-G showing appropriate 
response while use of higher standard concentrations.  
This has been hypothesized due to the parent compound being highly lipophilic and attaching to 
the VAMS device tip. Whereas its metabolites, being hydrophilic would get easily diffused into 
the aqueous-organic extraction solvent from the hydrophilic device tip.  
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5.4 Solvent Optimization 
Table 10: Solvents tested for Optimization 
 
In order to improve recovery of BUP, multiple other solvents were tested. Prewetting tips which 
incorporates a rehydration step prior to addition of extraction solvent was also tested, but no 









Use of LLE in order to improve extraction recovery of BUP was carried out using ethyl 
acetate and ammonium hydroxide. However, there was no significant improvement in peak 
response for the parent compound. 
The use of formic acid (FA) solution in water improved Buprenorphine recovery, 
however potential issues with the formation of a colored solution as well as peak area 
enhancement for the glucuronide metabolites had to be tackled.  
Upon review of literature, we found that Houbart et al. considered the proportion of 
organic solvent, acidic additive, and duration of shaking to optimize the extraction process for a 
VAMS method. Addition of formic acid improved recovery for a hydrophobic compound but at 
very low proportion[78]. Therefore, we reduced the proportion of acidic additive and tested the 
use of 0.1% formic acid instead of 1% formic acid solution. Since 5% Methanol showed good 
results for all the metabolites, addition of the 0.1% formic acid additive to the solvent was 
considered. 
 

























VAMS Duplicates (10 ng/ml)






5.5 Vortexing/Sonication optimization 
Along with this, the use of a more vigorous lateral shaker instead of sonication showed 
improvement in BUP recovery. With this, shaking for longer duration resulted in more effective 
blood desorption from the tips. Therefore, as pictured in Figure 14, use of a lateral shaker for 120 
minutes was considered optimum. 
 
Table 11:  VAMS Samples Std.Conc 5 ng/ml- Subjected to Sonication 
Name Area IS Area Response 
BUP-VAMS-Sonication-30 min 822.527 2864.75 0.287 
BUP-VAMS-Sonication-30 min 542.281 3449.287 0.157 
  
 
Table 12: BUP Response is Improved- Use of Lateral Shaker  
BUP_LateralShaker_VAMS_120 3854.6 5485.06 0.703 
BUP_LateralShaker_VAMS_120 3003.385 4629.668 0.649 
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Figure 14: Eberbach Lateral Shaker 
 
 
The primary challenge was to maintain the acceptable response for NBUP, NBUP-G and 
BUP-G while improving BUP recovery. Therefore, the final solvent used is 0.1% Formic acid in 
5% Methanol, along with the use of a lateral shaker for a period of 120 minutes to achieve 








5.6 Sample preparation 
Daily calibration standards, QC samples, and clinical blood samples were thawed at room 
temperature. Blood concentrations of buprenorphine, norbuprenorphine, buprenorphine 
glucuronide, norbuprenorphine glucuronide were determined by LC-MS/MS. VAMS and Blood 
samples were processed simultaneously in the same workflow.  
1. Calibration standards and QC samples were prepared by spiking blank human blood 
with stock solution, the range is from 1 -20 ng/mL, QC from 3, 9 and 18 ng/mL for BUP 
and NorBUP, range is 2-40 ng/mL, QC from 9, 18, 36 ng/mL for BUPG and NorBUPG  
2. VAMS tips were weighed once before spotting with blood (Dry weight) and once after 
absorption of blood (wet weight). This is for gravimetric volume estimation of the blood 
taken up by the device tip. 
3. The 20 μL VAMS tips were inserted into 1.5 ml Eppendorf tubes using the cap of the 
tube to detach the tip from its plastic handler. Simultaneously, 20 μLs of blood of the 
same concentration was pipetted into the 1.5 ml Eppendorf tubes.  
4. To this, 180 μL of extraction solvent was added. The solvent consisted of 0.1% formic 
acid in 5% Methanol solution. 
5. Tubes containing extraction solvent were subjected to shaking using a lateral shaker on 
HIGH for 120 minutes.  
6. Subsequently, 800 μL of 100% acetonitrile (ACN) which contains 500 pg/mL 
(buprenorphine-D4, norbuprenorphine-D3,), 1 ng/mL (buprenorphine-D4-3-β-D-
glucuronide, norbuprenorphine glucuronide-D3) was added to the samples.  
7. To this, the tube was vortexed for 30 s, then followed with centrifugation at 15,000 rpm 
for 12 min at 8 °C. 700 μL supernatant was transferred to a glass tube and was dried 
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under a stream of air.  
8. The dried residues were reconstituted in 100 μL of mobile phase (consisting of 2A:1B), 
vortexed for 30 s, and then transferred to an Eppendorf microcentrifuge tube. The tube 
was centrifuged at 15,000 rpm for 12 min at 8 °C. 
9.  The supernatant was transferred to a sample vial for injection. 5 μL of the solution was 















5.7 Bioanalytical method Validation 
The LC-MS/MS method was developed and validated according to the guidance of 
bioanalytical method validation by the FDA in 2013. 
Calibration curves 
The calibration curves were generated by plotting the response ratio of buprenorphine to 
buprenorphine-D4, norbuprenorphine to norbuprenorphine-D3, buprenorphine-3-β-D-
glucuronide to buprenorphine-D4-3-β-D-glucuronide, norbuprenorphine glucuronide to 
norbuprenorphine glucuronide-D3 against nominal concentration of the corresponding four 
analytes in blood samples. The calibration curves were fit by a quadratic equation using 
weighing factor of 1/x2. Concentration of analytes in the unknown blood samples were calculated 
from their peak area ratios and the calibration curve. The deviations of back calculated 
concentrations from the nominal concentrations of QC samples were used to check the assay 
performance over the concentration ranges on each sample run day. The acceptance criteria of 
accuracy and precision of QC samples are described below. 
 
Accuracy and precision 
Accuracy was investigated by intra- and inter-day coefficient of variation (CV). Quality 
control samples (3, 9, 18 ng/mL for buprenorphine and norbuprenorphine; 6, 18, 36 ng/mL for 
buprenorphine glucuronide and norbuprenorphine glucuronide) were tested. For intra-day 
accuracy, three samples of each QC concentration were analyzed on a single day; for inter-day 
accuracy, a total of three samples of each concentration were measured on three consecutive 
days. The back-calculated concentrations should be between 85% and 115% of the nominal 
concentrations. 
 51 
Precision was evaluated by intra- and inter-day reproducibility. Quality control samples 
(3, 9, 18 ng/mL for buprenorphine, 3, 9, 18 ng/mL for norbuprenorphine; 6, 18, 36 ng/mL for 
buprenorphine glucuronide and norbuprenorphine glucuronide) were tested. For intra-day 
precision, three samples of each concentration were assayed on a single day; for inter-day 
precisions, a total of three samples of each concentration were determined on three consecutive 
days. The intra-day and inter-day coefficient of variation should be within 15%. 
 
Extraction recovery and matrix effects 
The extraction recovery of buprenorphine and three of its metabolites was performed by 
comparing the responses obtained from neat standard QC samples (3, 9, 18 ng/mL for 
buprenorphine, 3, 9, 18 ng/mL for norbuprenorphine; 6, 18, 36 ng/mL for buprenorphine 
glucuronide and norbuprenorphine glucuronide) with the responses obtained from extracted 
blank human blood spiked with buprenorphine, norbuprenorphine, buprenorphine glucuronide 
and norbuprenorphine glucuronide and internal standards post extraction. 
To evaluate the effect of endogenous matrix on the ionization of buprenorphine and three 
metabolites, responses of buprenorphine and three metabolites at the QC concentrations (3, 9, 18 
ng/mL for buprenorphine and norbuprenorphine; 6, 18, 36 ng/mL for buprenorphine glucuronide 
and norbuprenorphine glucuronide) in triplicate were evaluated. The effect of blood matrix on 
analytes was defined by comparing the response obtained from extracted blank blood samples 
spiked with buprenorphine, norbuprenorphine, buprenorphine glucuronide and norbuprenorphine 
glucuronide post extraction with the absolute response of non-extracted methanolic solvent to 




It is crucial to understand the stability of VAMS samples since they would be subject to 
storage for a period of at least two days before reaching a clinical lab setting. Therefore, we 
tested the devices under multiple separate conditions reflective of clinical handling. They were 
stored at room temperature for a period of 24 hours, 3 days, and 4 days. One pair of samples was 
also stored at -80⁰ C for a period of 4 days. The samples were taken in duplicate at mid-level 9 






6.0  Results 
Following an injection of the reconstitution solution into LC-MS/MS system with 
positive ion electrospray ionization interface, the retention time of buprenorphine, 
norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide were 2.16, 
1.28, 1.1 and 0.83 min, respectively. The assay did not show any significant interference with 
blood constituent at the retention times of analytes of each ion pair for MRM.  
Typical chromatograms of blood samples spiked with buprenorphine at 2 ng/mL; 
norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide at 20 ng/mL, 
and their respective internal standards are listed in Figure 16. The regression coefficient (r2) of 
all calibration curves was higher than 0.98 for buprenorphine, buprenorphine glucuronide, and 
norbuprenorphine glucuronide. However, the standard curve for norbuprenorphine did not pass 











The ratio of mean peak area of the analytes to the internal standard was linearly related to 
the standard concentration of the compounds in the concentration range of 1-20 ng/mL for BUP 
and 2-40 ng/mL for BUPG and NorBUPG. However, NorBUP did not demonstrate linearity with 
significant Y intercept value of 0.75 and R-squared of 0.94. These are depicted in Figure 15.  
 
Figure 15: Standard Curves of VAMS samples for buprenorphine and its metabolites 
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Fig 15: (Continued) 
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Fig 15: (Continued) 

























     YIntercept




     Degrees of Freedom














Figure 16: Representative chromatogram spiked with buprenorphine (2 ng/mL, A), norbuprenorphine (20 ng/mL, B), buprenorphine glucuronide 
(20 ng/mL, C), and norbuprenorphine glucuronide (20 ng/mL, D) with their respective deuterated internal standards 
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6.2 Accuracy and Precision 
The LLOQ was determined as 1 ng/ml for BUP and NBUP. Intra-day and inter-day 
coefficients of variation (CV) were within acceptable limits according to the guidance on 
bioanalytical method validation for buprenorphine which is less than 15% for nominal 
concentrations and less than 20% for the lower limit of quantification (LLOQ).  The inter and 
intraday accuracy and precision of the control samples quantified without the use of VAMS in 
the same volume of blood standards has also been depicted in Table 14 and 16. 
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Table 13: VAMS- Inter-day and Intra-day accuracy of buprenorphine and three metabolites (expressed as a percentage of the nominal concentration) 
 
 











3 98.7       43.5 6 
87.3 
80.3 
9 108.7       74.7 18 
97.5 
98.5 






Inter- day accuracy (%, n=3) QC 
Concentration 
(ng/mL) 
Inter-day accuracy (%, n=3) 
3 111.9 103.3 6 
111.6 113 
9 99.3 73.5 18 
111.0 108 




Table 14: Controls-Inter-day and Intra-day accuracy of buprenorphine and three metabolites (expressed as percentage of nominal concentration) 










3 95.8 NA 6 107.2 164.9 
9 105.5 88.3 18 121.2 135.6 
18 78.9 82.2 36 87.6 89.7 
QC Concentration 
(ng/mL) 







3 96.7 NA 6 108.8 123 
9 118.3 121.3 18 117.6 113.8 





Table 15: VAMS-Inter-day and Intra-day precision of buprenorphine and three metabolites (expressed as coefficient of variation) 
 
 











3 6.4 6.3 6 22.8 10.7 
9 11.0 27.8 18 7.0 11.1 




Inter- day precision (%, n=3) QC 
Concentration 
(ng/mL) 
Inter-day precision (%, n=3) 
3 3.7 1.3 6 10.8 14.5 
9 8.3 12.6 18 5.5 1.5 
18 7.5 7.4 36 13.0 6.0 
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Table 16: Controls-Inter-day and Intra-day precision of buprenorphine and three metabolites (expressed as coefficient of variation) 
 
 











3 7.16 NA 6 11.8 12.1 
9 14.2 15.6 18 10.4 8.5 




Inter- day precision (%, n=3) QC 
Concentration 
(ng/mL) 
Inter-day precision (%, n=3) 
3 14.9 NA 6 17 35.4 
9 5.1 9.6 18 8.2 9.1 
18 7.6 41.5 36 17.4 7.7 
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6.3 Recovery  
The QC blood samples at different concentrations were processed to examine the 
recovery of buprenorphine and three metabolites. The recoveries for all analytes in VAMS 
samples were above 100% over the concentration range tested, and BUP showed acceptable 
recovery within range. The control samples showed recovery >70% for the same concentrations 
for BUP. However, the recovery for NBUP, BUPG and NBUPG were not within acceptable 
limits and exceeded 300% which indicates significant overestimation using the VAMS method. 















Table 17: Recovery of buprenorphine and its metabolites in VAMS and Control Samples 
 
 









Recovery for VAMS 
(%, n=3) 
3 109.2 NA 6 164.3 303.5 
9 113.3 NA 18 152.8 264.8 









Recovery for Control Samples 
(%, n=3) 
3 79.5 428.9 6 125.3 211.6 
9 81.1 259.3 18 107.4 219.4 
18 69.8 161.5 36 105.2 190.9 
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6.4 Matrix Effect 
In order to evaluate matrix effect, the post extraction addition protocol was followed. The 
response obtained by injecting analyte in standard solution (neat solvent of 50% methanol) was 
compared to that of post extract blank blood spiked with analyte at the same concentration. It 
was calculated using the formula: 




Where A is the peak area obtained of analyte in neat solvent, B is the peak area of the 
analyte in sample which underwent sample preparation and extraction and later spiked with 
analyte of the same concentration as the standard solution.  
Table 18: Matrix Effect for buprenorphine and its metabolites 
 
 









3 -18 NA 6 35.6 22.4 
9 -18.1 NA 18 30.5 20.3 





The VAMS samples were loaded with QC 9 ng/ml in duplicates and subjected to drying 
at room temperature for a period of 24 hours, 3 days, and 4 days. Two duplicate QC VAMS 
samples were also stored for a period of 4 days at -80⁰ C. All these samples were analyzed in a 
single run and compared to fresh VAMS samples from the same blood QC standard dried for a 
period of 3 hours on the day of analysis. 
 The changes in concentrations for buprenorphine and its three metabolites at the 9 ng/ml 
concentration of the QC samples were evaluated. There was no significant degradation of 
samples after storage at any of the conditions tested compared to the duplicates analyzed 
immediately after sampling, however the deviations between the duplicates were large. Results 




Table 19: Stability of VAMS samples 











Mean % ± SD 
9 3 days RT 80.4± 1.5 99.4±21.6 18 3 days RT 87.1±5.2 95.9±14.9 
9 Overnight RT 81.9±4.4 107.8±14 18 Overnight RT 92.3±7.2 104±21.6 
9 4 days RT 77.4±2.6 98.4±12.5 18 4 days RT 87.4±4.4 90.1±15.3 
9 4 days   -80⁰ C 81.3±10.9 98.5±1.6 18 4 days   -80⁰ C 92.6±2.8 89.4±7.6 
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7.0 Discussion 
Studies to evaluate the pharmacokinetics of buprenorphine and its metabolites have been 
conducted, typically using plasma or blood samples of large volumes. An assay developed for 
the same compounds in our lab utilized a plasma UPLC-MS/MS assay and evaluated pregnant 
subjects during the second and third trimester and postpartum. They found that CYP and UGT 
activities were significantly increased as evidenced based on the metabolic ratios of BUP during 
pregnancy vs postpartum. Therefore, there was a need to increase dose of BUP in pregnant 
women to account for the increased metabolism and to reach the same drug exposure in these 
patients as in non-pregnant subjects[82].   
In order to conduct a classical pharmacokinetic study, large volumes of 1-2 ml samples 
are required. These can represent a significant inconvenience to obtain from special populations 
including pregnant women, infants, and geriatrics. Advancements in bioanalytical technology 
has enabled determination of drug concentrations in extremely low volumes in the range of 20-
100 μLs. There is a need for development of a multiplex assay that can determine concentrations 
of multiple compounds from one sample itself, especially with ultra-low volumes. This enables 
optimization in the amount of pharmacokinetic data obtained from the smallest possible volume 
of sample collected[57].  
The specific special population we addressed in this study is opioid addicted pregnant 
women. Conducting pharmacokinetic studies in this population brings in unique challenges 
which need innovative strategies to combat. Data on drug use in pregnant women has been 
virtually nonexistent for decades. Some of the reasons for this include:  
1. Ethical concerns in including pregnant women in research studies 
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2. Concerns in affecting organogenesis of fetus and potential long-term exposure to infants 
3. Lack of financial incentive for conducting such studies 
4. Logistical issues to obtain blood samples for studies  
Therefore, dosing recommendations for pregnant women are extrapolated from non-
pregnant data obtained for the same drug, and most of these medications are used “off-
label”[83].  
We propose to make use of an opportunistic study by obtaining clinical data from 
pregnant women already receiving the drug buprenorphine as part of their clinical care. 
The objective of the current study was to develop and validate an LC-MS/MS method to 
simultaneously quantify buprenorphine and its metabolites using 20 µL blood VAMS samples. 
The method displayed linearity over a range of concentrations buprenorphine (1-20 ng/ml), 
buprenorphine glucuronide and norbuprenorphine glucuronide (2-40 ng/mL) with acceptable 
intra and inter day precision and accuracy for Buprenorphine. This is the first study conducted 
using Volumetric Absorptive Micro sampling to quantify buprenorphine and its metabolites.  
Greenwald et al. has demonstrated a strong relation between the occupancy of the mu 
opioid receptor and concentrations of Buprenorphine. Clinically, the concentration range for 
pregnant patients has been recommended to be above 1 ng/ml to prevent symptoms of 
withdrawal[84, 85]. At current dose ranges, pregnant patients have levels below 1 ng/ml which 
needs to be quantified using the VAMS method.  
The therapeutic blood concentrations of Buprenorphine are between 0.1 to 1 ng/ml, with 
a maximum of 2-3 ng/ml. This highlights the limitation of our study in poor sensitivity for 
detecting concentrations of the parent drug below 1 ng/ml. Further work has to be done in order 
to improve sensitivity of the method. We have to consider using a higher volume of blood to 
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suitably quantify the metabolites, either by use of a 30 µL VAMS device or by processing two 
separate 20 µL VAMS tips separately for Buprenorphine and the metabolites by different 
extraction methodologies.  
Optimizing extraction of the compound was the most critical step in developing this 
assay.  
In order to maximize recovery, we tested multiple solvents and 
vortexing/sonication/shaking conditions. Use of a methanol-water based solvent along with an 
acidic additive formic acid proved to give the best extraction recovery. Sonication was concluded 
to be ineffective since the VAMS tip structure would not allow ultrasonic frequencies to 
penetrate the pores, rather it would absorb the sound, making blood desorption difficult. For the 
current method, use of a lateral shaker for a long duration made a significant impact in 
improving recovery of the parent compound buprenorphine. 
 Protein precipitation, liquid-liquid extraction and solid-phase extraction are the three 
common methods used to remove interfering compounds from blood samples. Among these, the 
use of liquid-liquid extraction was tested. However, it is unsuitable due to the wide-ranging 
polarity of each of the four analytes. We employed protein precipitation using acetonitrile to 
maximize extraction recovery from the VAMS device tip.  
As discussed in Section 5.3, we optimized the extraction recovery by utilizing aqueous 
solvent with organic component and an acid modifier. The use of formic acid in low proportion 
enhanced extraction recovery of all compounds, however it led to formation of colored solutions 
and enhancement in peak response for glucuronide metabolites. The mechanism by which the 
presence of 5% Methanol and 0.1% formic acid aids in improving extraction recovery is 
unknown but can be hypothesized as an effect of strong solvation ability of methanol coupled 
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with the aqueous concentration would lead to significant desorption of blood from the VAMS 
polymer tip. 
Validation of the assay methodology was carried out to demonstrate acceptable accuracy 
and precision in both VAMS and Control samples for buprenorphine. However, there are 
significant inconsistencies observed for norbuprenorphine and the glucuronide metabolites for 
linearity, accuracy, precision, recovery, and matrix effect.  
Stability was evaluated at the mid-level QC concentration in duplicate for four 
conditions: 24 hours at RT, 3 days and 4 days at RT, 4 days at -80⁰ C. All samples were within 
an acceptable range compared to QC samples analyzed within 3 hours of drying on the same day, 
despite deviations between each duplicate sample being large. However, more rigorous long term 
stability studies need to be performed to make conclusive statements about VAMS integrity 
when stored under extreme temperatures.  
In conclusion, further validation studies need to be conducted for norbuprenorphine, 
buprenorphine glucuronide and norbuprenorphine glucuronide. The assay demonstrates validity 
for the parent compound buprenorphine itself. Therefore, the assay methodology developed is 










We have developed and validated a rapid, sensitive, and robust UPLC-MS/MS assay with 
simple sample preparation to quantify the concentration of buprenorphine in 20 µL VAMS blood 
samples. The advantages of this analytical method include simple sample processing, ultra-low 
volume requirement, acceptable recovery of BUP and short sample run time.  
Since our end goal for the study is to understand the time course of change in CYP 
enzyme expression throughout pregnancy and post-partum by looking at parent drug to 
metabolite ratios, further work is needed to quantify norbuprenorphine, buprenorphine 
glucuronide and norbuprenorphine glucuronide. However, majority of the clinical effect in 
mediating relief of withdrawal symptoms for opioid addicted patients is due to buprenorphine 
and not the metabolites. Therefore, it is far more important to quantify the parent drug compared 
to the metabolites for these patients, from a clinical point of view.  
This assay enables us to quantify concentration time profiles of buprenorphine, after low 










9.0 Future Directions 
Additional work has to be carried to validate the assay methodology for the metabolites 
of buprenorphine. We are currently collecting samples from pregnant patients at Magee 
Women’s Hospital Pittsburgh to apply this assay methodology on 20 µL samples. The major aim 
is to enable at-home sampling without the need of a nurse, wherein patients can send in their own 
fingerpick samples to the lab. Use of VAMS obviates the need for special storage conditions, and 
needs simple air drying for a period of few hours before analysis.  
We plan to utilize the data obtained from patient samples to characterize the 
pharmacokinetic profile of buprenorphine by comparing metabolite ratios during and after 
pregnancy. This enables dose optimization in these patients, and on a larger basis, monitoring of 
drug levels at the same time. Even though buprenorphine is not a drug that is routinely 
monitored, maintaining drug levels is critical to avoid adverse withdrawal symptoms or craving 
in these patients.  
Moreover, the use of VAMS can be extended to perform other studies in pregnancy, 
wherein contributions of genotype within the enzyme change can also be quantified.  
The primary goal is to establish simple research design to conduct studies within 
pregnancy such that the patient can perform sampling at home and demonstrate increased 
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